Results 191 to 200 of about 14,494 (232)

Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide

Obesity, 2022
AbstractObjectiveSwitching from tenofovir disoproxil fumarate (TDF)‐ to tenofovir alafenamide (TAF)‐containing antiretroviral therapy may negatively influence weight, cholesterol, and atherosclerotic cardiovascular disease risk. The extent of these changes and their association with TAF remain unclear.MethodsThis retrospective cohort evaluated ...
Jason J. Schafer, Matty Zimmerman, Ciara Walshe, Jesse Cerankowski, Ayako Shimada, Scott W. Keith   +5 more
openaire   +2 more sources

The Effect of Rifampicin on the Plasma and Intracellular Pharmacokinetics of Tenofovir Alafenamide Fumarate in Participants with HIV-associated Tuberculosis.

Journal of Acquired Immune Deficiency Syndromes
BACKGROUND Rifampicin reduces plasma tenofovir and intracellular tenofovir diphosphate (TFV-DP) concentrations when co-administered with tenofovir alafenamide fumarate (TAF).
Rephaim Mpofu, N. Chandiwana, Simiso M Sokhela, Michelle A. Moorhouse, Francois Venter, P. Anderson, L. Wiesner, Marta Boffito, G. Maartens, P. Sinxadi   +9 more
semanticscholar   +1 more source

Partial post-exposure protection by topical inserts containing tenofovir alafenamide fumarate/elvitegravir in a macaque model of rectal SHIV infection.

Journal of Infectious Diseases
On-demand topical inserts for HIV prevention may be a good option for people who have a low frequency of sexual activity. We recently demonstrated in a preclinical macaque model that rectal application of inserts containing tenofovir alafenamide fumarate
Natalia Makarova, Tyana Singletary, M. Peet, Kristen Kelley, Ryan Johnson, V. Agrahari, Maria Mendoza, Yi Pan, W. Heneine, Meredith R Clark, J. García-Lerma, Gustavo F. Doncel, James M. Smith   +12 more
semanticscholar   +1 more source

Tenofovir Alafenamide Fumarate Therapy for HIV Treatment: Cardiometabolic and Renal Safety

AIDS Research and Human Retroviruses, 2020
Antiretroviral treatment based on tenofovir alafenamide fumarate (TAF) is increasingly recommended, as it maintains the viral suppression and improves renal function and bone density in comparison with tenofovir disoproxil fumarate (TDF). We carried out a retrospective cohort study including experienced patients who switched treatment from TDF to TAF ...
Vasilis, Petrakis, Periklis, Panagopoulos, Stella, Papachristou, Nikolaos, Papanas, Irene, Terzi, Grigorios, Trypsianis, Dimitrios, Papazoglou   +6 more
openaire   +2 more sources

Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)

Biochemical Pharmacology, 2016
Tenofovir alafenamide (TAF) can be considered a new prodrug of tenofovir (TFV), as successor of tenofovir disoproxil fumarate (TDF). It is in vivo as potent against human immunodeficiency virus (HIV) at a 30-fold lower dose (10mg) than TDF (300mg). TAF has been approved in November 2015 (in the US and EU), as a single-tablet regimen (STR) containing ...
openaire   +2 more sources

Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2

Diagnostic Microbiology and Infectious Disease, 2019
Tenofovir-associated renal toxicity is influenced by several factors, including plasma exposure and genetic variants in transporter-encoding genes. Tenofovir plasma exposure has been associated with a polymorphism in SLC28A2 gene (encoding the concentrative nucleoside transporter 2, CNT2): particularly, SLC28A2 124 CT/TT genotype patients show higher ...
Cusato J., Calcagno A., De Nicolo A., Mogyorosi K., D'Avolio A., Di Perri G., Bonora S.   +6 more
openaire   +2 more sources

[Tenofovir alafenamide fumarate - a new generation of tenofovir].

Klinicka mikrobiologie a infekcni lekarstvi, 2018
Antiretroviral therapy as a life-long treatment has to meet the criteria of maximum efficiency while maintaining the highest possible level of safety and tolerance. Tenofovir disoproxil fumarate (TDF) is an antiretroviral drug with an excellent effect of virological suppression.
Svatava, Snopková, Kateřina, Havlíčková, Petr, Husa   +2 more
openaire   +1 more source

Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate

Journal of Gastroenterology and Hepatology, 2019
AbstractBackground and AimTenofovir alafenamide (TAF) is a new prodrug of tenofovir, enabling treatment of patients with hepatitis B virus (HBV) infection at a lower dose than tenofovir disoproxil fumarate (TDF), via more efficient delivery of tenofovir to the hepatocytes.
Shun Kaneko, Masayuki Kurosaki, Nobuharu Tamaki, Jun Itakura, Tsuguru Hayashi, Sakura Kirino, Leona Osawa, Keiya Watakabe, Mao Okada, Wan Wang, Takao Shimizu, Mayu Higuchi, Kenta Takaura, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Yuka Takahashi, Mamoru Watanabe, Namiki Izumi   +18 more
openaire   +2 more sources

Tenofovir alafenamide compared to tenofovir disoproxil fumarate, induces dysglycemia, and dyslipidemia in Wistar rats

AIDS
Objectives: To determine the metabolic effects of tenofovir alafenamide (TAF) compared to tenofovir disoproxil fumarate (TDF) in vivo. Design and methods: Male Wistar rats (Rattus novergicus, 250–300 g body weight) were divided into three groups (n = 8) and orally treated daily with
Rajendraparsad, Hurchund, Sinegugu E, Sibiya, Bernard O, Owaga, Peter M O, Owira   +3 more
openaire   +2 more sources

Dolutegravir/emtricitabine/tenofovir-alafenamide/tenofovir-disoproxil-fumarate

Reactions Weekly, 2022
openaire   +1 more source